Trial intelligence / Profile preview

Early 68Ga-DOTATATE PET/CT Prognostic Assessment in 177Lu-oxodotreotide-treated Grade 2 GEP-NETs

2025-524942-87-00Phase 4Authorised

Sponsor: Centre Eugène Marquis
Start: May 2026
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
Countries: 1

Overview

Phase 4, open-label, single-arm trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, sponsored by Centre Eugène Marquis. Primary endpoint: Progression-free survival (PFS) by RECIST 1.1 from first 177Lu-oxodotreotide injection. Planned start May 2026; status: authorised.

Drugs

lutetium Lu 177 dotatate

Conditions

Gastroenteropancreatic Carcinoid Tumor

Beyond the preview

Go deeper on 2025-524942-87-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-524942-87-00.